Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312. SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally. The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations. The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy. |
Demi Moore, 61, says fullJodie TurnerAmal Clooney played key role in ICC bid to request arrest warrants for Israeli PM and Hamas leaderRays openingWho is Abi Carter? Inside the American Idol winner's unconventional family lifePadres second baseman Xander Bogaerts leaves game against Braves with shoulder injuryRishi Sunak to apologise for worst treatment disaster in NHS historyJude Bellingham's new model girlfriend Laura Celia Valk looks sensational in a figureColton Herta shows speed as Honda fights back in penultimate Indy 500 practice sessionBrewers starter Joe Ross leaves after first inning vs. Marlins with lower back strain